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ABSTRACT 
Harboring the apolipoprotein E4 (APOE4) allele is the greatest genetic risk factor 
associated with late-onset (sporadic) Alzheimer’s disease (AD), however the mechanism 
by which apoE4 contributes to the pathology of AD is unknown. The proteolysis of 
apoE4 has been suggested to contribute to AD pathology due to a possible toxic gain, or 
loss of function. In order to determine if apoE4 is being cleaved, we designed and 
characterized a site-directed cleavage antibody directed at position D151 of full length 
human apoE4. The antibody (nApoECFp17) detected a predicted ~17 kDa fragment 
following incubation with the proteases Type-1 collagenase, and matrix 
metalloproteinase (MMP)-1and 9. Once the nApoECFp17 amino-terminal antibody was 
applied to frontal cortex AD brain sections, it revealed nuclear labeling of glial cells and 
neurofibrillary tangles (NFTs). In addition, nApoECFp17 regionally localized with the 
protease MMP-9 in plaque-rich regions in vivo, suggesting apoE4 may be cleaved 
extracellularly. Together these data suggest a novel cleavage event of apoE4 by Type-I 
collagenase and MMP-1 and 9, generating an amino-terminal fragment that is then taken 
up by glial cells and localizes to the nucleus. This fragment localizing to the nucleus 
purposes a new role of apoE4 in AD pathology where apoE may alter gene expression. 
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INTRODUCTION 
Although the first case of Alzheimer’s disease (AD) was described more than 100 
years ago, there is still no cure or any effective treatments for this disease. It is known 
that AD is pathologically characterized by the presence of beta amyloid plaques (Aβ-
plaques) and neurofibrillary tangles (NFTs). Current dogma suggests that Aβ formation 
precedes the formation of NFTs and collectively has become known as the Amyloid 
Cascade Hypothesis. Current AD research is focused on either targeting the initial 
formation of Aβ-plaques, and/or how Aβ-plaques and NFTs cause their toxic effects in 
the brain. The focus of my thesis investigates the role of apolipoprotein E (apoE) 
proteolysis in promoting AD pathology. The proteolysis of apoE may drive AD 
pathology by either gaining a new toxic function, losing its normal function, or both. Due 
to the possible loss and/or gain of function following proteolysis of apoE, the research 
conducted in this work focuses on apoE’s production of a toxic fragment that may 
influence NFT and Aβ-plaque formation. 
The Brain 
The brain is a very complex organ both in structure and function in the human 
body. The brain connects us with our world by allowing us to interact with sensory 
stimuli. It is vital in connecting us with one another by processing language and emotion. 
Most importantly, the cerebral cortex of the brain is responsible for many of the higher 
executive functions that contribute to distinguishing humans from other species. The 
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brain is a very powerful organ of which we have only scratched the surface in 
discovering its true capabilities. 
The human central nervous system consists of the brain and spinal cord. Through 
a network of nerve cells and connections, information from the central nervous system is 
distributed throughout the body. The brain is composed of grey matter (cell bodies, 
dendrites, and axon terminals of neurons) and white matter (axons that connect parts of 
the grey matter together), which is encased in a bony structure called the cranium. The 
brain consists of two cell types, neurons and glial cells. Neurons are specialized cells that 
transmit nerve impulses, and are the fundamental units of the nervous system. The 
structure of a neuron consists of a central cell body housing the nucleus, an axon for 
signal transduction, and dendrites for receiving information. The brain is composed of 
roughly 100 billion neurons, however, there are 10-50 times that number of glial cells in 
the human brain. Unlike the communication functionality of neurons, glial cell function is 
to protect and support neurons. Glial cells provide oxygen, insulation, hold neurons in 
place, and clean up cellular debris. There are three types of glial cells; 1) astrocytes, 
which are star-like cells that link neurons to blood vessels 2) oligodendrocytes, which 
support and insulate axons and 3) microglia, which are systemically analogous to white 
blood cells. 
Alzheimer’s Disease 
Alzheimer’s disease (AD) is a progressive, irreversible neurodegenerative disease 
characterized by neuronal death and synaptic pruning [1]. AD is the most common form 
of dementia and results in memory deficits, language difficulties, impairment of 
visuospatial abilities, as well as other cognitive impairments [2]. Currently, AD affects 
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over 5 million people in the United States alone and annually costs the national 
healthcare system over 243 billion dollars. The high cost to care for those afflicted with 
AD emphasizes the importance of discovering preventative strategies, and effective 
treatments in hopes of a cure. 
Currently, the mechanisms associated with AD pathology are unclear. However, 
the involvement of Aβ plaques appear to be central in leading to neuronal degeneration. 
Aβ plaques are insoluble aggregates of the amyloid β peptide that collect in the brain 
parenchyma surrounding neurons and glial cells. Production of Aβ results from the 
proteolysis of the amyloid precursor protein (APP) by either α, β, or γ secretases [3]. The 
β secretase cleaves APP, resulting in a soluble amino terminal fragment containing 
extracellular sequences of APP. However, cleavage of APP by the α secretase results in a 
soluble amino terminal fragment, as well as a carboxyl-terminal membrane bound 
fragment. The γ secretase can further cleave the membrane-bound carboxyl-terminal 
fragment or the amino-terminal fragments producing Aβ. The increase in Aβ leads to 
induction of oxidative stress, apoptosis, and disrupted axonal transport, ultimately 
resulting in defective cognitive ability and NFT pathology [3]. 
Research suggests the protein tau contributes to NFT formation in AD. Tau is a 
microtubule associated protein (MAP) and is expressed in the neuronal axon. Tau 
normally functions to stabilize the cytoskeleton by binding to microtubules and also plays 
a role in anterograde transport in neurons and glial cells. Tau can be hyperphosphorylated 
resulting in a decreased binding affinity to microtubules and subsequent aggregation of 
tau into beta sheet structures termed paired helical filaments (PHFs), which then 
aggregate as rope-like structures composed of two fibers twisted around one another [4]. 
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The loss of function of tau in AD decreases the ability of microtubules to bind to tubulin 
for proper assembly and polymerization, increasing the occurrence of aggregating tau 
binding to normal tau [5]. 
Alzheimer’s Disease Diagnosis and Treatment Strategies 
Clinical diagnosis of AD is primarily made by exclusion of other causes of 
dementia. A true diagnosis of AD can only be obtained by performing an autopsy with 
post mortem tissue analysis [6]. Thus, there is a demand for biomarkers associated with 
AD, not only for proper diagnosis, but also to determine susceptibility to AD and to 
assess treatment strategies. Currently, there are no prevention measures that can be taken 
for AD. Drugs on the market to aid with AD treatment are designed to maintain synapses 
and overall neuron function. Examples of AD drug targets are: the hyperphosphorylation 
of tau, NMDA receptor blockade, acetylcholinesterase inhibition or nicotinic receptor 
agonists, and neurotransmitter balance [7]. Aside from the therapeutic approach to help 
control symptoms of AD, disease modifying strategies are also under investigation aimed 
at reducing Aβ levels in the brain and reestablishing tau function. In order to achieve this 
goal, current gene therapy techniques such as lentiviruses or viral vectors are becoming 
more popular [8], as well as cell replacement therapies [9]. Very new on the horizon is 
analyzing the epigenetic component of AD, which could be useful for determining 
biomarkers and predisposition [10]. 
Risk Factors in Alzheimer’s Disease 
The greatest risk factor for AD is advancing age with current statistics indicating 
that 11 percent of those age 65 and older and 32 percent of people age 85 and older are 
afflicted with this disease [11]. There are two types of AD: early-onset familial AD 
5 
 
 
(before age 65) and late-onset or sporadic AD. Early-onset AD is caused by mutations in 
the amyloid precursor protein (APP) or presenilin-1 (PSEN 1) and presenilin-2 (PSEN 2) 
genes. Mutations in these proteins ultimately enhance production of Aβ, which leads to 
an increase in Aβ-plaque deposition. Additionally, the increase in plaque formation could 
be due to a failure to remove or clear Aβ from the brain, contributing to AD pathogenesis. 
Several genetic risk factors are also associated with late-onset AD such as A2M 
(encoding alpha-2-macroglobulin), ABCA1 and 2 (encoding ATP-binding cassette 
transporters 1 and 2, respectively), CLU (encoding clusterin), PICALM (encoding the 
phosphatidylinositol binding clathrin assembly protein) and SORL1 (encoding sortilin-
related receptor gene) TREM2, and APOE4. There are two variants of TREM2 that 
increase the risk of AD by three fold by either stimulating phagocytic activity or by 
decreasing microglial pro-inflammatory responses [12]. However, the greatest genetic 
risk factor is harboring the apolipoprotein E4 (APOE4) allele. The inheritance of one 
copy of APOE4 increases the risk of AD four fold, while inheritance of two copies raises 
the risk about tenfold. Despite the well-known risk associated with inheritance of the 
APOE4 allele, the mechanism by which the apoE4 protein contributes to AD pathology 
has not been definitively established. 
APOE Structure and Function 
Human apoE is polymorphic with three major isoforms, apoE2, apoE3, and 
apoE4, which differ by a single amino acid substitution involving cysteine-arginine 
replacements at positions 112 and 158 [13]. Harboring the APOE3 allele is believed to 
neither increase nor decrease one’s risk of AD, having the E2 form may actually decrease 
one’s risk, while having the E4 allele increases risk. Structurally, apoE4 is a 34 kDa 
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protein composed of 299 amino acids and contains two major domains, referred to as the 
N-terminal and C-terminal domains, which are connected by a short-hinge region [14] . 
ApoE is expressed by astrocytes, some microglia, and in certain circumstances neurons 
[15]. In the CNS, apoE functions to transport cholesterol to neurons through binding and 
uptake by apoE low density lipoprotein (LDL) receptors [16]. Cholesterol released from 
apoE-containing lipoprotein particles is used to support synaptogenesis and the 
maintenance of synaptic connections [17]. Differences among apoE isoforms in these 
processes may negatively impact synaptic plasticity or recovery of neurons from 
neurodegeneration as might occur in AD [18]. 
Proteolysis of APOE 
ApoE4 plays a normal role in lipoprotein transport in the brain, however the 
mechanism by which apoE4 contributes to AD pathogenesis remains elusive. It has been 
hypothesized that apoE4 is much more susceptible to proteolysis than the E2 or E3 form 
due to the numerous proteolytic cleavage sites in the hinge region of apoE4 [19]. 
Although the hinge region is particularly susceptible to proteolysis, there is evidence to 
support other susceptible regions of apoE4 such as the N-terminal and C-terminal 
domains [20]. In mouse models, production of apoE by neurons is associated with apoE 
fragmentation, whereas production of apoE by astrocytes is not [19]. Neuronal 
proteolysis of apoE4 occurs preferentially in regions of the brain that are susceptible to 
AD and neurodegeneration [21]. Additionally, proteolysis of apoE4 occurs to a greater 
extent than for apoE3, and is associated with enhanced phosphorylation of tau [21]. There 
are several studies that have demonstrated the presence of fragmented apoE4 in the AD 
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brain [19, 21, 22], supporting the hypothesis that the proteolysis of apoE4 could 
contribute to neuropathology and neurodegeneration in AD. 
When apoE4 is cleaved, two distinct domains are produced and each are 
associated with a specific pathological structure in the AD brain; the C-terminal domain 
of apoE4 binds to beta amyloid and primarily localizes to plaques [22, 23], while the N-
terminal domain mainly localizes to NFTs [19]. ApoE4 fragments produced by 
proteolytic cleavage have been found to be associated with either a toxic gain of function 
or a loss of normal function. Altered function of apoE4 due to the high susceptibility of 
apoE4 to proteolysis may be responsible for the heightened risk associated with 
inheritance of the APOE4 allele. 
APOE Proteolysis Leads to a Loss of Function 
The main function for apoE in the CNS is to transport cholesterol. As mentioned 
previously, proteolysis of apoE occurs in neurons, not in astrocytes. In normal conditions, 
neurons express very little apoE. However, expression of apoE is increased in neurons 
under circumstances requiring neuronal repair, remodeling, and response to injury [24, 
25]. ApoE may be providing the necessary cholesterol for neuronal repair as well as 
synapse formation, plasticity, and repair [26]. The efficiency of apoE4 to transport 
cholesterol and maintain neurons in response to injury may be reduced when compared 
with the E2 and E3 isoforms and this could be due to lower levels of the apoE protein in 
the brain following proteolysis of the protein [27]. 
In addition to the role of apoE in cholesterol transport, apoE also plays a role in 
the clearance of Aβ deposition in the AD brain. It is hypothesized that apoE binds to Aβ 
and induces a pathological β-sheet conformational change in Aβ [28]. Studies have 
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reported that apoE3 and E2 form more stable complexes with Aβ and to a much greater 
extent than E4 [29], and therefore, the better binding efficiency of apoE3 and E2 may 
enhance Aβ clearance compared with apoE4 [30]. In a recent study, an AD mouse model 
crossed with mice expressing C-terminal-truncated apoE4 showed these mice had a lower 
affinity for beta amyloid and reduced ability to clear beta amyloid [31]. Additionally, the 
APOE allele dosage is associated with increased plaque deposits in AD [32]. In a large 
cerebrospinal fluid (CSF) study of cognitively normal middle-aged people (“at risk” for 
AD), Aβ deposition was associated with low CSF levels of Aβ42 [34]. In carriers of the 
APOE4 allele, lower CFS levels of Aβ42 were observed, emphasizing analysis of CSF 
levels as pre-clinical detection tool for tracking of AD in “at risk” individuals [33]. 
APOE Proteolysis Leads to a Toxic Gain of Function 
The proteolytic cleavage of apoE4 not only may lead to a loss of function, but it 
may also produce a toxic-gain of function. The cleavage of apoE4 produces N- and C- 
terminal fragments that are neurotoxic in nature [22, 34, 35]. It has been hypothesized 
that these fragments are generated following intraneuronal processing of apoE4 [22]. The 
N-terminal fragment containing the receptor binding region of apoE4 (1-191) is 
responsible for binding with tau [36] as well as the hyperphosphorylation of tau, a key 
step in the evolution of NFTs [21]. The neurotoxicity of N-terminal fragments may also 
promote the underlying pathology of AD by producing tangle-like inclusions, which are 
similar to early NFTs both in vitro and in animal models [19, 34, 35]. The C-terminal 
fragment containing the lipid- binding region (171-272) of apoE4 interacts with 
mitochondria and C-terminal fragments have been shown to impair function and integrity 
of mitochondria [34]. In addition, apoE4  fragments may lead to mitochondrial 
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dysfunction by binding to mitochondrial proteins and enzymes and altering their 
activities [37]. Another possible toxic gain of function involves oxidative stress. In this 
regard, a specific fragment of apoE4 promotes cellular uptake of extracellular Aβ leading 
to the formation of reactive oxygen species [38]. Finally, in a transgenic AD mouse 
model, expression of a C-terminal-truncated fragment of apoE4 resulted in behavioral 
deficits and a failure to clear Aβ deposition [31]. These results support the notion that 
fragments produced from the proteolysis of apoE4 gain a toxic function and enhance the 
underlying pathological mechanisms of AD. 
Hypothesis 
The exact nature of the protease involved in cleaving apoE4 is unknown although 
several candidate proteases have been reported including cathepsin D [39], a 
chymotrypsin-like protease [19], aspartic proteases [40], and caspases [23]. Previous 
studies on the proteolysis of apoE4 in AD have identified the presence of a ~18 kDa band 
in the human AD brain extracts, suggesting cleavage near position D154 of the mature 
form of apoE4 (299 amino acids) [19, 22]. This site was chosen based on it being a 
putative caspase consensus cleavage site. Rohn et al. synthesized and characterized a site-
directed cleavage antibody aimed at specifically recognizing this ~18 kDa fragment of 
apoE4 found in AD samples. However, results indicated a protease other than caspase 
was cleaving apoE4 at this site. Therefore, examination of an additional caspase-cleavage 
consensus site with apoE4 was undertaken that would produce a slightly smaller amino-
terminal fragment (~17 kDa) following putative cleavage of apoE4 by caspase-3 [23]. 
Thus, an additional site-directed antibody was designed to target position D151 just 
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upstream of D154 [23], which will be referred to as nApoECFp17 for the duration of this 
work. 
Matrix metalloproteinases (MMPs) are a family of calcium-requiring and zinc-
containing endopeptidases and evidence has suggested that MMPs may play an important 
role in the pathogenesis of AD [41]. Type IV collagenase or MMP-9 is a major MMP that 
is expressed and released by neurons, microglia, and astrocytes [42]. MMP-9 has also 
been identified in neuroinflammation [42]. ApoE4 has been previously associated with 
brain inflammation and AD patients with the E4 allele show increased microglial 
activation compared with AD patients not carrying the E4 allele [43].  In a study 
conducted by Dafinis et al., a particular apoE4 fragment lead to increased extracellular 
levels of MMP-9 [38]. The hypothesis tested in my thesis is that full length apoE4 is a 
target for proteolytic cleavage by MMP-9, resulting in a predicted ~17 kDa fragment and 
this fragment is present in the AD brain. 
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METHODS 
Materials 
Human recombinant apoE4 and E3 proteins purified from E. coli were purchased 
from ProSci Inc. (Poway, CA). Activated human recombinant caspase-3 was purchased 
from Calbiochem (San Diego, CA). The anti-apoE4 N-terminal full-length rabbit 
polyclonal antibody was purchased from Aviva Systems Biology Corp. (San Diego, CA). 
PHF-1 was a generous gift from Dr. Peter Davies (Albert Einstein College of Medicine, 
Bronx, NY). Type I collagenase was from Sigma-Aldrich (St. Louis, MO) and purified 
collagenase was from Worthington Biochemical (Lakewood, NJ). Active MMP-1 and the 
mouse monoclonal MMP-9 antibody were purchased from Abcam Inc. (Cambridge, 
MA), while active MMP-9 was purchased from EMD Millipore (Billerica, MA). The 
monoclonal antibodies, Olig-1 and Iba1/AFI1, were purchased from EMD Millipore 
(Billerica, MA). 
Generation of the Polyclonal Site-Directed Cleavage Antibody to ApoE4 
Synthesis of polyclonal antibodies was accomplished using the 7-mer peptide C-
RKRLLRD, which represents the N-terminal upstream neoepitope fragment of apoE4 
generated following cleavage after the aspartic acid residue located at position D151 of 
the mature form of apoE4. Following synthesis, this peptide was coupled to KLH and 
injected into two rabbits. The resulting sera (verified by ELISAs, Fig. 2) were used to 
affinity purify antibodies using a Sulfolink™ column (Thermo Scientific) coupled with 
the peptide used as an immunogen. For this antibody, synthesis of peptides, injections of 
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immunogens, and collection of antisera were contracted out to Bethyl laboratories 
(Montgomery, TX). 
ELISA 
To verify the polyclonal site-directed cleavage antibody, 40µl of the N-terminal 
neopeptide fragment of apoE4 following cleavage at position D151 was mixed with 
coating buffer and added to 32 wells of a Dynex plate, covered, and incubated overnight 
on a rocker at 4°C. TTBS (pH 7.5) was used to wash the plate after each incubation. 300 
µl of blocking buffer was added to each well and was covered to incubate for 1 hour at 
37° C. Dilutions of the pre-immunized and immunized sera ranged from 1:250- 1:32000. 
The 1:250 dilution contained 4 µl of either pre-immunized or immunized serum and 996 
µl of diluting buffer. Serial dilution was carried out until the 1:32000 dilution. After the 
blocking stage, each dilution was added to the corresponding well and incubated for 2 
hours at 37°C. The secondary antibody was a 1:5000 dilution of horseradish peroxidase 
(HRP). The plate was washed and 100 µl of the secondary solution was added to each 
well to incubate for 1 hour at 37°C. The plate was washed and 100 µl of TMB Microwell 
Peroxidase substrate was added to each well. After 4 minutes, 100 µl TMB Stop solution 
was added to each well. The plate was then read at a wavelength of 450 nm.  
Cell-free assays/Western Blots 
For the proteolysis of apoE4, 40 µg of purified human recombinant apoE4 was 
incubated with active human recombinant caspase-3 at 37° C overnight in 2x reaction 
buffer containing 10 mM DTT. Type I collagenase, purified collagenase, MMP-1, and 9 
experiments were carried out utilizing a reaction buffer containing 100 mM Tris-HCL, 10 
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mM CaCl₂, pH 7.8. The reactions were terminated by adding 5x sample buffer and were 
stored at -20° C. 
For Western blot analysis, samples were separated by 15% SDS PAGE (sodium 
dodecyl sulfate polyacrylamide gel electrophoresis) and transferred to nitrocellulose. 
Transferred gel slabs were stained in Coomassie blue to verify equal loading between 
samples. Nitrocellulose membranes were incubated in nApoE4CF antibody (1:500) 
overnight at 4°C and primary antibodies were visualized using goat anti-rabbit HRP-
linked secondary antibody, incubated for 1 hour at room temperature (1:5,000; Jackson’s 
Laboratory, West Grove, PA), followed by ECL detection. 
Immunoprecipitation and Mass Spectrometry 
Immunoprecipitation experiments were conducted by incubating the 
nApoECFp17 antibody with apoE4 samples digested with Type I collagenase. To 
terminate the actions of Type I collagenase, 100 mM EDTA (ethylenediamine tetra-acetic 
acid) was added at the conclusion of the experiment. Samples were incubated overnight 
at 4°C with nApoECFp17 antibody and then 50 µl of Protein A agarose beads were added 
for 2 hours at 4°C. The agarose beads were then spun down and washed 3X in PBS. 
Samples were prepared for Western blot analysis as described above utilizing a 
commercial antibody that recognizes the extreme amino-terminus of full-length apoE4. 
For mass spectrometry experiment samples were separated by 15% SDS PAGE 
and gel slices were excised from SDS-PAGE gels and digested with trypsin. Briefly, 
excised bands were destained in 25 mM ammonium bicarbonate/50% acetonitrile 
overnight at 4°C. Gel slices were dehydrated in 100% acetonitrile for 10 minutes at room 
temperature, followed by reduction in 10 mM DTT for 60 minutes at 37°C. Next, 
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alkylation was performed in 55 mM iodoacetamide for 60 minutes at room temperature in 
the dark. Protein samples were digested with trypsin in 10 mM ammonium bicarbonate 
overnight at 30°C. Digested peptides were separated using reversed phase 
chromatography (Thermo Scientific Easy-nLC II) and infused into a Velos Pro Dual-
Pressure Linear Ion Trap Mass Spectrometer for MS/MS using CID fragmentation. 
Results were analyzed with Thermo Scientific’s Proteome Discoverer software (v1.3) and 
the Mascot search engine probing the human SwissProt database. Search parameters 
included carbamidomethyl (C) fixed modification, oxidation (M) variable modification, 
maximum of 2 missed cleavages, and 1.5 Da peptide mass tolerance. 
Human Subjects 
Autopsy brain tissue from the frontal cortex of nine neuropathologically 
confirmed AD cases with known apoE isoform genotype and three age-matched control 
cases were studied. Fixed frontal cortex tissue sections used in this study were provided 
by the Institute for Memory Impairments and Neurological Disorders at the University of 
California, Irvine. Approval from Boise State University Institutional Review Board was 
not obtained due to the exemption granted that all tissue sections were fixed and received 
from University of California, Irvine. Brain tissue obtained from University of California, 
Irvine were anonymized and never identified except by case number. Tissue donors or 
their next of kin provided signed informed consents to the Institute for Memory 
Impairments and Neurological Disorders for the use of their tissues in research (IRB 
2014–1526). Case demographics are presented in Table 1. 
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Immunohistochemistry 
Free-floating 40 μm-thick serial sections were used for immunohistochemistry 
and immunofluorescence as previously described above. For bright-field labeling, 
sections were washed with 0.1 M Tris-buffered saline (TBS), pH 7.4, and then pretreated 
with 3% hydrogen peroxide in 10% methanol to block endogenous peroxidase activity. 
Sections were subsequently washed in TBS with 0.1% Triton X-100 (TBS-A) and then 
blocked for thirty minutes in TBS-A with 3% bovine serum albumin (TBS-B). Sections 
were further incubated overnight at room temperature with the antibodies at the described 
concentrations above. Following two washes with TBS-A and a wash in TBS-B, sections 
were incubated in anti-rabbit or mouse biotinylated anti-IgG (1 hour) and then in avidin 
biotin complex (1 hour) (ABC, Elite Immunoperoxidase, Vector Laboratories, 
Burlingame, CA, USA). The primary antibody was visualized using brown DAB 
substrate (Vector Laboratories). 
Immunofluorescence Microscopy 
For immunofluorescence co-localization studies, experiments were initiated by 
incubating in primary antibody overnight followed by application of the ABC, Elite 
Immunoperoxidase kit on day 2 (Vector Laboratories, Burlingame, CA, USA). In this 
case, instead of completing the staining use DAB substrate, we employed Alexa fluor 
488-labeled tyramide (green, Ex/ Em=495/519) that was purchased as part of the TSA 
(Tyramide signal amplification) kit #12 (Life technologies, Green Island, NY). Following 
labeling with the primary antibody, sections were washed 3X in Tris buffer followed by 
incubations in Tris A (15 minutes) and Tris B (30 minutes). Sections were then incubated 
with the second primary antibody overnight at room temperature. On day 3, sections were 
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incubated with secondary biotinylated-SP (long spacer) AffiniPuregoat anti-mouse or 
rabbit IgG for 1 hour (Jackson Immuno Research Labs (West Grove, PA). This was 
followed by incubation in streptavidin Alexa Fluor 555 conjugate for 1 hour (Life 
technologies, Green Island, NY). Following 3X washes in Tris buffer, sections were 
mounted and cover slipped using Pro-Long Gold Antifade with DAPI (Life 
technologies). To determine if cross-reactivity to reagents was a factor in double-labeling 
experiments, experiments were replicated with the antibodies in reverse. 
An Olympus BX60 microscope with fluorescence capability equipped with a 
MagnaFire SP software system for photomicrography was employed for microscopic 
observation and photomicrography of the diaminobenzidine (DAB)-labeled and 
fluorescent sections. The fluorescent molecules were excited with a 100-W mercury 
lamp. Fluorescent-labeled molecules were detected using a filter set having a 460–500-
nm wavelength band pass excitation filter, a 505-nm dichroic beam splitter, and a 510–
560-nm band pass emission filter. 
Confocal Microscopy 
For confocal immunofluorescence imaging, the primary antibodies were 
visualized with secondary antibodies tagged with either Alexa Fluor 488 or Alexa Fluor 
555 (Invitrogen, Carlsbad, CA). Images were taken with a Zeiss LSM510 Metasystem 
combined with the Zeiss Axiovert Observer Z1inverted microscope and ZEN2009 
imaging software (Carl Zeiss, Inc., Thornwood, NY). Confocal Z-stack and single plane 
images were acquired with an Argon (488 nm) and a HeNe (543 nm) laser source. Z-
stacks images were acquired using a 20x Plan-Apochromat (NA 0.8) objective, emission 
band passes of 505–550 nm for the detection of the green channel, Alexa Fluor 488 and 
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550–600 nm for detection of the red channel, Alexa Fluor 555. All images displayed are 
2-D, maximal intensity projections generated acquired Z-stacks. Single plane images 
were acquired with a 63x Plan-Apochromat oil-immersion objective (NA 1.4) with 
emission long pass of 505 nm for the detection of the green channel using Alexa Fluor 
488 and 550–600 nm for the detection of the red channel using Alexa Fluor 555. 
Quantification and Statistical Analysis 
Statistical difference between the average number of nApoE4CFp17-positive 
NFTs in 3 AD cases from each allelic combination of ApoE3/ApoE3, ApoE3/ApoE4, and 
ApoE4/ApoE4A was determined using Student’s two-tailed T-test. To determine the 
percent co-localization, a semi-quantitative analysis was performed by taking 40X 
immunofluorescence, overlapping images from three different fields in frontal cortex 
brain sections of three separate AD cases. Capturing was accomplished by using a 2.5x 
photo eyepiece and a Sony high resolution CCD (charged-coupled device) video camera 
(XC-77). As an example, to determine the percent co-localization between Iba-1 and 
nApoE4CFp17, photographs were analyzed by counting the total number of double-
labeled cells per 40X field for each case, and the number of cells labeled with each 
antibody alone. Statistical differences in this study were determined using Student’s two-
tailed T-test employing Microsoft Office Excel. 
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RESULTS 
In a previous study, we identified a ~17 kDa band when incubating human 
recombinant apoE with activated caspase-3 [23]. Based on results from that study, we 
designed a site-directed cleavage antibody based on a caspase-cleavage recognition site at 
position D151 (LLRD) of the full-length form of apoE4 that would give a predicted 
amino-terminal fragment of ~17 kDa (Fig. 1). Following synthesis of a 7-mer peptide 
RKRLLRD, this peptide was coupled to KLH and injected into rabbits. Peptide-specific 
anitbodies were affinity purified from resulting sera, which was verified by ELISA (Fig. 
2). Western blot analysis was performed to determine if nApoECFp17 could label the 
predicted 17 kDa fragment following incubation with caspase-3. Figure 3A shows that 
we were unable to detect any band following incubation of full-length apoE4 with 
caspase-3. We hypothesized that since apoE4 is a secreted protein, any potential protease 
would be located extracellularly, therefore we next tested collagenase. Incubation of 
recombinant apoE4 with Type I collagenase generated a ~17 kDa fragment that was 
detected by nApoECFp17 (Fig. 3A, second lane, left panel). The nApoECFp17 antibody 
did not react with full-length apoE4, nor did the antibody detect any fragments following 
incubation with recombinant apoE3 (Fig. 3A, left panel). To confirm the specificity of 
nApoECFp17, we preformed immunoprecipitation experiments by incubating 
nApoECFp17 with apoE4 that had been digested with Type I collagenase. The 
nApoECFp17 antibody immunoprecipitated a ~17 kDa fragment that was detected by 
Western blot using an apoE4 antibody whose epitope is at the extreme amino-terminus of 
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apoE4 (Fig. 3B). Additionally, mass spectrometry of the 17 kDa band indicated 77% 
sequence coverage of amino acids 1-151 of apoE4. 
The Type I collagenase originally used was a bacterial collagenase preparation 
that included collagenase, caseinase, clostripain, and tryptic activities. The experiments 
were performed again using purified collagenase as well as MMP-9 and MMP-1 given 
that the MMPs have a high degree of homology with collagenase. When apoE4 was 
cleaved by purified collagenase, high molecular weight bands were produced that were 
detected by nApoECFp17 (Fig. 3C, left panel). These high molecular weight bands 
suggest that the cleavage of apoE4 may result in aggregation. Incubation of full-length 
apoE4 with MMP-9 produced similar results as Type I collagenase, however, incubation 
with MMP-1 produced a high-molecular weight band only when the concentration of 
recombinant apoE4 was doubled (Fig. 3C, left panel). These results suggest 
nApoECFp17 detects an amino-terminal fragment of apoE of ~17 kDa at the cleavage 
site D151, and that MMP-9 can generate this fragment in vitro. In addition, Western blot 
analysis following incubation of apoE3 with MMP-9 indicated that apoE3 is also 
proteolyzed generating in this case only high molecular weight bands (Fig. 5). 
To further test the specificity of the nApoECFp17 antibody, an amino-terminal 
protein fragment of apoE4 was synthesized corresponding to the predicted length 
following cleavage at D151. This amino-terminal fragment (herein termed apoE41-151) 
also contained a 6X histidine (His) tag to facilitate purification from E. coli. In this 
manner, the 6X His tag was attached either at the N-terminal end of apoE41-151 or to the 
C-terminal end of apoE41-151. The addition of the His tag to this fragment greatly 
influenced whether the nApoECFp17 antibody recognized the fragment. Thus, when the 
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His tag was attached to the C-terminal end of apoE41-151, there was limited detection by 
nApoECFp17 in either ELISA assays (Fig. 4A) or Western blot analysis (Fig. 4B). We 
interpret these data to suggest that the addition of the His tag to the C-terminal end of 
apoE41-151 prevented the nApoECFp17 from binding to its epitope on the C-terminal end 
of the fragment. These data further support the specificity of the nApoECF-17 antibody 
for the C-terminal region of apoE4 following cleavage at D151. 
After Western blot analysis confirmed the cleavage of apoE4 in vitro, 
immunohistochemical experiments were done using postmortem frontal cortex brain 
sections from AD cases. In order to establish the staining profile of nApoECFp17 
antibody labeling in AD brain sections, single label, bright-field experiments were carried 
out. The results indicated immunoreactivity by the nApoECFp17 antibody in all AD 
cases examined. The strongest labeling was in neurons (Fig. 6A and B), neuropil threads 
(PHFs with abnormally phosphorylated tau protein) in plaque regions (Fig. 6C), blood 
vessels (Fig 6D), and small circular structures in gray and white matter (Fig. 6E). 
Additional experiments supported the specificity of the nApoECFp17 antibody 
including a lack of staining observed following application of preimmune serum, and 
preadsorption of the affinity-purified antibody with the immunogenic peptide, which 
significantly reduced labeling in serial AD sections (Fig. 7A-D). In addition, there was no 
staining of the nApoECFp17 antibody in aged matched controls, and when AD cases 
were compared with normal cases, there was a significant increase in the number of 
labeled nuclei in AD cases (p=0.0004) (Fig. 7E and F). 
Due to the small size of the circular structures, we hypothesized that the labeling 
was occurring in the nuclei of glia cells. To test the nuclear localization of nApoECFp17 
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in glia cells, the glial markers Iba-1 (to detect microglia), Olig-1 (to detect 
oligodendrocytes, and GFAP (Glial fibrillay acidic protein) (to detect astrocytes) were 
used. In each case, 4’6-diamidino-2-phenylindole (DAPI) was used as the nuclear stain to 
verify the staining that was being observed was nuclear. In Figure 8 A-D and I, the merge 
of the staining of Iba-1, DAPI, and nApoECFp17 in representative frontal cortex AD 
sections indicated approximately 80% of microglia were labeled by nApoECFp17 
antibody. Additionally, the merge of Olig-1, DAPI, and nApoECFp17 indicated about 
27% of oligodendrocytes were labeled with the nApoECFp17 antibody (Fig. 8 E-H, J). 
There was no co-localization of nApoECFp17 with GFAP under similar experimental 
conditions (Fig. 8 K-M). 
To confirm whether the amino terminal fragment labeled by nApoECFp17 
localizes to NFTs as opposed to plaques, double label experiments were conducted with 
the two known tangle markers AT8 and PHF-1. The presence of nApoECFp17 was 
present in fibrillary tangles, a subset of NFTs that were labeled by PHF-1. However, 
nApoECFp17 also stained neurons that were negative for AT8 or PHF-1 (Fig. 9). 
In a final set of experiments, we examined whether nApoECFp17 labeling occurs 
together with MMP-9, an extracellular protease that was able to generate the predicted 
~17 kDa fragment in vitro (Fig. 3C). As an initial approach, we screened representative 
frontal cortex brain sections from AD subjects using bright-field microscopy in single-
label experiments utilizing a human anti-MMP-9 monoclonal antibody. The presence of 
MMP-9 was evident within plaque-rich regions in outer cortical layers and appeared to be 
extracellular as expected (Fig. 10A and B). Next, double-label confocal 
immunofluorescence experiments were undertaken using the same MMP-9 antibody 
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together with nApoECFp17. In this case, although there was no co-localization between 
the two antibodies, the two markers did occur within close proximity to one another 
raising the possibility that MMP-9 may cleave apoE4 in vivo (Fig. 10C-E). 
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DISCUSSION 
Harboring the APOE4 allele increases risk for AD, however, despite exhaustive 
efforts, the mechanism responsible for enhanced risk of harboring this allele remains 
elusive. What separates apoE4 from the other isoforms (E3 and E2) is that apoE4 is more 
susceptible to proteolysis and produces fragments that are neurotoxic in nature [19, 34, 
35]. In order to identify these fragments in the human AD brain, we designed a site-
directed cleavage antibody targeting position D151 of full-length mature form of human 
apoE4. In vitro, this antibody, which we have termed the nApoECFp17 antibody, 
specifically labels an amino-terminal fragment of apoE4 of the correct predicted 
molecular weight of ~17 kDa fragment following cleavage at position D151. Most 
importantly, nApoECFp17 does not interact with full-length apoE4 or E3. Generation of 
this amino-terminal fragment and recognition by nApoECFp17 was only observed with 
recombinant apoE4 and not E3 following digestion with Type I collagenase. In addition, 
immunoprecipitation pull-down experiments using the nApoECFp17 antibody revealed a 
~17 kDa fragment that was detected by a commercial antibody whose epitope was 
located at the extreme amino-terminus of full-length apoE4. Mass spectrometry of the 
~17 kDa fragment indicated a 77% sequence coverage of amino acids 1-151 of apoE4. 
That the epitope for the nApoCFp17 antibody is at the C-terminal end of this amino-
terminal fragment was confirmed following synthesis of ApoE4 1-151 protein fragments. 
A 6X histidine (His) tag was incorporated either at the N- or C-terminal end of ApoE41-
151 to facilitate purification from E. coli. ELISA and Western blot results indicated that 
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the nApoECFp17 antibody was only able to recognize ApoE41-151 in which the His tag 
was attached to the amino-terminal end. Additional experiments in situ using postmortem 
frontal cortex brain sections confirmed the specificity of the nApoECFp17 antibody. 
These immunohistochemical experiments included showing co-localization of 
nApoECFp17 within NFTs and not plaques. Previous studies emphasize this concept of 
amino-terminal fragments localizing specifically with NFTs while carboxyl-terminated 
fragments contribute to AD pathology in aiding in the formation of NFTs, but localize to 
plaques only [19, 22, 23]. Moreover, labeling by nApoECFp17 was prevented following 
preadsorption experiments with the peptide corresponding to the upstream sequence 
(RKRLLRD) that would be generated following cleavage of apoE4 at position D151. 
ApoE is primarily synthesized and secreted from astrocytes and microglia [15], 
but surprisingly, nApoECFp17 strongly labeled nuclei of glial cells as well as NFTs. 
These data suggest that the nApoECFp17 labeled fragment is being cleaved 
extracellularly then taken up by microglia. The amino terminal end of apoE4 includes the 
low-density lipoprotein (LDL) binding domain for full-length apoE because the receptor 
binding region of apoE is 134-151 [15, 19]. The preferential interaction of apoE4 to the 
LDL receptor is due to the arginine at position 112 [44], however the low-density 
lipoprotein receptor protein (LRP) in the same family as the LDL receptor and undergoes 
rapid and constitutive endocytosis. LRP has been suggested to mediate the neuronal 
uptake of cholesterol and other lipids including apoE. The amino-terminal fragment 
produced following cleavage at position D151 may interact with the low-density LRP 
binding region and be taken up by microglia through receptor mediated endocytosis and 
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trafficked to the nucleus. The function of this fragment in nucleus of microglia requires 
further research, but one possible role could be to alter gene expression. 
The final important result from these experiments is that collagenases and MMPs 
are potential proteases capable of cleaving apoE4 or E3. Although the preferential 
proteolysis of apoE4 versus E3 and E2 has been well documented, the exact nature of the 
protease(s) involved in this process has not been definitively identified. In our hands, 
MMP-1 and collagenase produced high-molecular weight complexes in vitro following 
incubation with recombinant apoE4 that were identified following Western blot analysis 
with nApoECFp17. Similar experiments utilizing active MMP-9 were of particular 
interest because it produced the predicted ~17 kDa fragment recognized by nApoECFp17 
following Western blot analysis. Additionally, in the AD brain, nApoECFp17-labeled 
nuclei of microglia were identified in the same areas of the extracellular MMP-9 labeling 
(in plaque-rich regions), which is consistent with where microglia are typically found. 
These data support previous findings showing increased extracellular levels of MMP-9 in 
AD [38] and the breakdown and loss of the integrity of the blood-brain barrier associated 
with AD [45]. 
Together, the results from my thesis suggest a novel role for an amino-terminal 
fragment found in the AD brain. The work from my thesis sets up the stage for further 
research into the mechanism by which apoE4 fragments may be affecting AD 
pathogenesis. The novel finding of the nApoECFp17 labeled amino-terminal fragment 
localizing in the nuclei of microglia offers opportunities to study how this fragment may 
be affecting gene expression. Currently, our lab is continuing to analyze how this 
fragment is internalized through the LRP or LDL receptors using a microglial cell line. 
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Since full-length apoE4 has been thought to traffic to the nucleus and up or down 
regulate various gene expression such as genes associated with apoptosis, pro-
inflammatory cytokines, and microtubule assembly [46], analysis of RNA sequence data 
may shed light into how this fragment affects either signaling pathways or the APOE4 
gene itself. The heightened risk associated with inheritance of the APOE4 allele has been 
hypothesized to stem from the susceptibility of apoE4 to proteolysis more than the E3 or 
E2 forms. Moreover, the enhanced susceptibility of apoE4 to proteolysis suggests apoE4 
loses function or gains toxic functions that contribute to AD pathology, but 
mechanistically remain unexplained. By understanding proteases that are involved in the 
cleavage of apoE4 and how the resulting fragments affect cells in the brain, it could 
ultimately be determined how the fragments affect cell signaling pathways or gene 
expression and establish the role of apoE4 in late-onset AD pathology. 
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FIGURES 
 
 
Figure 1: Synthesis of the nApoECFp17 antibody 
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Figure 2: ELISA: Verification of the polyclonal site-directed cleavage antibody 
ApoE4 titers in immunized rabbits. Pre-immune rabbit serum (red line) measured at an 
absorbance of 450 nm at dilutions from 1:250-1:32,000. And the immunized rabbit serum 
(blue line) confirms the high titer of n ApoECFp17 antibody in sera from immunized 
rabbits.  
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Figure 3: Characterization of a novel site-directed cleavage antibody to 
fragmented apoE4. (A): Preincubation of human recombinant apoE4 but not apoE3 with 
Type I collagenase for 1.5 hours at 37°C results in the generation of a 17 kDa fragment 
recognized by affinity-purified nApoECFp17 antibody (lane 2) following Western blot 
analysis. The right panel depicts the transferred gel slab that was stained with Coomassie 
blue revealing full-length apoE4 and E3 (34 kDa) as well as the associated fragmentation 
pattern following incubation with Type I collagenase. (B): Immunoprecipitation 
experiment with the nApoECFp17 antibody following incubation of full-length apoE4 
with Type I collagenase revealed the presence of a ~17 kDa band on a Coomassie gel 
(left panel) that resulted in an immunoreactive band by Western blot using an animo-
terminal specific antibody to apoE4 (arrowhead, right panel). (C) Identical experiments 
as in Panel A with the exception that purified collagenase (lane 2), MMP-1 (lanes 3 and 
5), or MMP-9 (lane 4) were incubated with recombinant apoE4 (see methods and 
materials for details). Incubation of apoE4 with either purified collagenase as well as 
MMP-1 resulted in the presence of high-molecular weight bands detected by 
nApoECFp17 following Western blot analysis, while incubation of MMP-9 resulted in 
the detection of a 17 kDa band similar to that generated by Type I collagenase. MMP-1 
generated a detectable band only when the apoE4 concentration was doubled (compare 
lanes 3 vs. 5). In both A and C note the specificity of the nApoECFp17 for cleaved 
fragments of apoE4 while no reactivity to full-length apoE was observed. 
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Figure 4: Specificity of nApoECFp17 to the amino terminal of ApoE 1-151. (A) 
ELISA assays in which 96-well plates were coated overnight at 4°C with either ApoE41-
151 with the His tag attached to the C-terminal end (red line), or with the His tag attached 
to the N-terminal end (blue line). The results indicated that the nApoECFp17 antibody 
only recognized ApoE51-151 in which the His tag was attached to the N-terminal end. 
(B) Similar experiments as in Panel A were performed using Western blot analysis. In 
this case, the nApoECFp17 antibody preferentially immunolabeled the apoE4 fragment in 
which the His-tag was localized to the amino-terminal end (Right panel). The left panel 
shows the identical experiment in utilizing an anti-His antibody that easily labeled both 
protein fragments regardless of the location of the His tag. 
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Figure 5: Incubation of apoE3 with MMP-9 generates high-molecular weight 
bands. Full-length recombinant apoE3 or apoE4 was incubated with activated MMP-9 
for 24 hours at 37° C and reactions were terminated by the addition of 5X sample buffer. 
Protein samples were separated on 15% SDS-PAGE gels, transferred to nitrocellulose, 
and the probed with the nApoECFp17 antibody overnight at 1:500. The Ctl lane is full 
length apoE3 protein incubated in the absence of MMP-9. 
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Figure 6: Detection of fragmented apoE in the frontal cortex of the Alzheimer’s 
disease brain. Representation bright-field staining in AD frontal cortex tissue sections 
following application of the nApoeCFp17 antibody. Low (A) and high (B) magnification 
of neurons llustrate the apparent loss of cell body integrity in the majority of neurons 
labeled with the nApoECFp17 antibody. Staining was also observed in neuropil threads 
within plaque-rich regions (C), along blood vesses (D), and the strongest labeling was 
within small circular structures throughout both gray and white matter  (E). All scale bars 
represent 10 µm. 
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Figure 7: Specificity of the nApoECFp17 antibody labeling in the Alzheimer’s 
disease brain. (A and B): Serial AD frontal cortex sections were immunolabeled with 
immunized serum (A) or preimmune serum (B) with specific staining only observed 
following application of immunized serum. Arrows in Panel A point to stained nuclei 
following application of immunized serum. (C and D): Serial AD frontal cortex sections 
were incubated with nApoECFp17 antibody alone (C), or following preadsorption with 
the peptide used as an immunogen (D). Staining was largely prevented following 
preadsorption with peptide (D). (E): Relative lack of labeling by nApoECFp17 in a 
representative neuropathologically normal case. (F): Panel (i) depicts quantitative results 
of the number of nApoECFp17-labeled nuclei in neuropathologically normal cases (NPN, 
green bars, N=3) and in AD cases (red bars, N=9) following staining of frontal cortex 
sections with nApoECFp17. For each case, the number of labeled nuclei was counted in a 
40X field (N=3 fields, ±SEM). The data indicated a significant increase in the number of 
nuclei labeled in AD cases (p= .0004). Panel (ii) illustrates quantitative analysis of the 
number of nApoECFp17-positive nuclei (per 40 µm field, 3 different fields, ±SEM) in 
specific APOE allele AD cases (N=2). Although higher numbers of nApoECFp17-
positive nuclei were observed for the APOE 4/4 group as compared to the other 
genotypes, a significant difference (p<0.5) was only observed following comparison of 
the APOE 4/4 group to 3/4. 
34 
 
 
 
Figure 8: Nuclear localization of an N-terminal fragment of apoE within 
microglia of the AD brain. (A-D): Representative images from confocal 
immunofluorescence in AD utilizing the nuclear stain, DAPI, (A), nApoECFp17 (B), the 
microglial specific marker, Iba1 (C), with the overlap image shown in (D). Note the 
strong nuclear localization of the nApoECFp17 antibody (arrow) within labeled 
microglia. (E-H): Identical to Panels A-D with the exception that the oligodendrocyte 
marker, Olig-1, was employed to specifically label oligodendrocytes. (I-J): 
Quantification of microglia (I) or oligodendrocytes (J) double-labeled with nApoECFp17 
indicated co-localization in 80% and 27.5% of microglia and oligodendrocytes, 
respectively. Data show the number of Iba1- or Olig-1-labeled cells alone (blue bars), 
number of nApoECFp17-labeled nuclei (green bars), and the number of cells with both 
antibodies (red bars) identified in a 40X field within frontal cortex AD sections by 
immunofluorescence microscopy (n = 3 fields for 3 different AD cases). (K-M): In 
contrast to the nuclear localization of nApoECFp17 within microglia and 
oligodendrocytes, confocal immunofluorescence double-label experiments with 
nApoECFp17 and the astrocytic marker, GFAP, failed to produce any co-localization 
between these two markers. Scale bars K-M represent 10 µm. 
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Figure 9: Localization of an amino-terminal fragment of ApoE within a subset 
of NFTs of the AD brain. (A-F) Confocal immunofluorescence double-labeling in 
representative frontal cortex sections of the AD brain utilizing the nApoECFp17 antibody 
(green), the tangle marker AT8 (red), and the overlap image showed in (F), but not in the 
majority of neurons labeled with nApoECFp17 (C). (G-H) Identical to panels A-F with 
the exception that the mature tangle marker PHF-1 (red) was used. A subset of fibrillar 
NFTs showed strong co-localization of the nApoECFp17 and PHF-1 (arrowhead I) in 
contrast to AT8 labeling. The blue fluorescence in Panels F and I represent the nuclear 
stain, DAPI. 
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Figure 10: Regional co-localization of extracellular MMP-9 surrounding 
nApoECFp17 labeled neurons in the AD brain. (A-B) Representative bright field 
microscopy in AD frontal cortex brain sections in single label experiments utilizing an 
antibody to MMP-9 labeling gray matter at low magnification (A) and high magnification 
(B). Localization appeared to occur in extracellular plaque-rich regions. (C-E) Confocal 
immunofluorescence double-labeling in representative frontal cortex sections of the AD 
brain utilizing nApoECFp17 (green), MMP-9 (red) reveal regional localization of the two 
antibodies, but not co-localization in the merged image (E). 
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TABLES 
Table 1: Case Demographics 
Group Age (yrs) Sex Cause of death APOE Genotype 
AD 71 M AD 3/3 
AD 61 F AD 3/4 
AD 80 F Dehydration 4/4 
AD 83 F Cardiac Arrest 3/3 
AD 75 F AD 3/4 
AD 65 F AD N/A 
AD 76 M AD 3/3 
AD 77 F Cardiac Arrest N/A 
AD 77 F Sepsis 4/4 
NPN 74 F Cancer N/A 
NPN 65 F Cardiac Arrest N/A 
NPN 67 F Heart Failure N/A 
NPN= neuropathologically normal  
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